Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Medgenics Inc Common Stock (MDGN) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 190,680
  • Shares Outstanding, K 37,080
  • Annual Sales, $ 0 K
  • Annual Income, $ -37,990 K
  • 36-Month Beta 1.18
  • Price/Sales N/A
  • Price/Book 4.38

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.00 +25.00%
on 11/03/16
5.95 -15.97%
on 11/17/16
+0.57 (+12.87%)
since 11/02/16
3-Month
4.00 +25.00%
on 11/03/16
5.95 -15.97%
on 11/17/16
-0.55 (-9.91%)
since 09/02/16
52-Week
3.09 +61.81%
on 02/11/16
6.89 -27.43%
on 12/03/15
-1.90 (-27.54%)
since 12/02/15

Most Recent Stories

More News
Medgenics to Present at the Jefferies London Healthcare Conference

PHILADELPHIA, PA--(Marketwired - Nov 9, 2016) -  Medgenics, Inc. (NASDAQ: MDGN) today announced that Michael F. Cola, President and Chief Executive Officer, will present at the Jefferies London Healthcare...

Medgenics to Present at the Jefferies London Healthcare Conference

PHILADELPHIA, PA--(Marketwired - Nov 9, 2016) -  Medgenics, Inc. (NASDAQ: MDGN) today announced that Michael F. Cola, President and Chief Executive Officer, will present at the Jefferies London Healthcare...

Medgenics to Present at the Jefferies London Healthcare Conference

PHILADELPHIA, PA--(Marketwired - Nov 9, 2016) -  Medgenics, Inc. (NASDAQ: MDGN) today announced that Michael F. Cola, President and Chief Executive Officer, will present at the Jefferies London Healthcare...

Medgenics to Present at the Jefferies London Healthcare Conference

PHILADELPHIA, PA--(Marketwired - Nov 9, 2016) -  Medgenics, Inc. (NASDAQ: MDGN) today announced that Michael F. Cola, President and Chief Executive Officer, will present at the Jefferies London Healthcare...

Medgenics Reports Third Quarter 2016 Financial Results

PHILADELPHIA, PA--(Marketwired - Nov 3, 2016) - Medgenics, Inc. (NASDAQ: MDGN)

Medgenics Reports Third Quarter 2016 Financial Results

PHILADELPHIA, PA--(Marketwired - Nov 3, 2016) - Medgenics, Inc. (NASDAQ: MDGN)

Medgenics Presents New Data Showing Prevalence of Genetic Mutations in Pediatric Populations with Attention Deficit Hyperactivity Disorder

Medgenics, Inc. (NASDAQ: MDGN) - New data presented at AACAP's 63rd Annual Meeting (Oct. 24-29, 2016 in New York, NY) confirmed the presence of specific genetic mutations in many children with Attention...

Medgenics to Host Conference Call to Announce Third Quarter 2016 Financial Results

PHILADELPHIA, PA--(Marketwired - Oct 26, 2016) - Medgenics, Inc. (NASDAQ: MDGN) will host a conference call and live audio webcast on Thursday, November 3, 2016 at 8:30 a.m. EST to report financial results...

Medgenics to Host Conference Call to Announce Third Quarter 2016 Financial Results

PHILADELPHIA, PA--(Marketwired - Oct 26, 2016) - Medgenics, Inc. (NASDAQ: MDGN) will host a conference call and live audio webcast on Thursday, November 3, 2016 at 8:30 a.m. EST to report financial results...

Medgenics, Inc. to Begin Trading on NASDAQ Global Market

PHILADELPHIA, PA--(Marketwired - Oct 10, 2016) - Medgenics, Inc. (NYSE MKT: MDGN) (the "Company") announced today that it has been approved for listing on the NASDAQ Global Market, continuing to trade...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

Medgenics, Inc. is a medical technology and therapeutics company focused on providing sustained protein therapies. The Company's Biopump Platform Technology uses the patient's own tissue for the treatment of a range of chronic diseases. Its products include EPODURE focused on the treatment of chronic...

See More

Support & Resistance

2nd Resistance Point 5.21
1st Resistance Point 5.11
Last Price 5.00
1st Support Level 4.93
2nd Support Level 4.85

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.